Feature|Videos|September 30, 2024
The Regulatory Stance on Oligonucleotide Enantiomers
Author(s)LCGC Editors
The panel dives into the regulatory stance on oligonucleotide enantiomers. The role of batch-to-batch reproducibility, new drug application (NDA) filing, and current guidelines are covered.
Advertisement
Episodes in this series
Regulatory guidelines must be considered when discussing oligonucleotide analysis and enantiomers. The panel reviews the current regulatory stance on this topic and common analytical bottlenecks relative to regulatory compliance.
Advertisement
Advertisement
Advertisement
Trending on LCGC International
1
"One-Shot" Solutions for Preparative Chiral Sub/Supercritical Fluid Chromatography Using Chiroptical Detection
2
GC-MS Tracks Buried Oil's Decades-Long Breakdown
3
Supercritical Fluid Chromatography: Advances, Applications, and Sustainability
4
LC-MS/MS Reveals Vitamin D Levels in Zoo Rhinos
5